Roche (RHHBY) will buy privately-held, California-based Therapeutic Human Polyclonals for $56.5 million. THP has developed transgenic rabbits, which it uses to create monoclonal and polyclonal human antibodies. THP, which has a German subsidiary, will be integrated into the Roche Pharma Center of Excellence for Protein Research organization in Penzberg, Germany. THP was founded in 2002. >>> Discuss This Story
